Patrick Forde MD, PhD, MBBCh

Dr. Patrick Forde completed training in internal medicine and oncology in Ireland prior to undertaking a further fellowship at Johns Hopkins. He became Professor of Oncology and has also served as Co-Director of the Division of Upper Aerodigestive Malignancies at Johns Hopkins and director of the multidisciplinary Thoracic Oncology Clinical Research Program.

He has led the development of a clinical-translational research program focused on the immuno-oncology of upper aerodigestive malignancies. Dr. Forde's research examines the role of immunotherapy for mesothelioma and lung cancer, and his work has led to the development of several ongoing phase 3 trials. In 2022, his work over several years led to the first FDA approval of neoadjuvant chemo-immunotherapy for the treatment of surgically operable lung cancer. He has published extensively in the field of immuno-oncology across the New England Journal of Medicine, Nature, and Nature Medicine.